Carfilzomib: A cause of drug associated thrombotic microangiopathy

被引：28
|
作者：
Qaqish, Ibrahim [1 ]
Schlam, Ilana M. [2 ]
Chakkera, Harini A. [1 ]
Fonseca, Rafael [2 ]
Adamski, Jill [3 ]
机构：
[1] Mayo Clin Arizona, Dept Nephrol, 5777 East Mayo Blvd, Phoenix, AZ 85054 USA
[2] Mayo Clin Arizona, Dept Internal Med, 5777 East Mayo Blvd, Phoenix, AZ 85054 USA
[3] Mayo Clin Arizona, Dept Lab Med & Pathol, 5777 East Mayo Blvd, Phoenix, AZ 85054 USA
来源：
TRANSFUSION AND APHERESIS SCIENCE | 2016年 / 54卷 / 03期
关键词：
Thrombotic microangiopathy; Therapeutic plasma exchange; Apheresis; BORTEZOMIB; PATIENT; EXPERIENCE;
D O I：
10.1016/j.transci.2016.03.002
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Carfilzomib is a selective proteosome inhibitor approved for treatment of relapsed and refractory multiple myeloma. Recent reports have linked exposure to carfilzomib with development of thrombotic microangiopathy (TMA). We describe two cases of biopsy proven thrombotic microangiopathy that occurred after the initiation of carfilzomib (dosed at 32 mg/m(2) and 23 mg/m(2), respectively) for relapsed multiple myeloma. Both patients were managed with discontinuation of the drug, therapeutic plasma exchange (TPE) and supportive care. Hemoglobin, platelets and renal function did not improve with TPE. TMA resolved with creatinine returning to baseline several weeks after discontinuation of the drug. The outcomes suggest that TPE is not beneficial for treating carfilzomib-induced TMA. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码：401 / 404
页数：4
相关论文
共 50 条
  • [31] Thrombotic microangiopathy associated with malignant hypertension
    Rifkin, BS
    Brewster, UC
    MAYO CLINIC PROCEEDINGS, 2006, 81 (05) : 593 - 593
  • [32] CANCER-ASSOCIATED THROMBOTIC MICROANGIOPATHY
    Rode, Shomita
    Parker, William A.
    Reed, Mark
    Johnson, Jeremy C.
    Kalanjeri, Satish
    CHEST, 2024, 166 (04) : 2317A - 2318A
  • [33] THROMBOTIC MICROANGIOPATHY ASSOCIATED WITH SQUAMOUS CARCINOMA
    TAPP, E
    RALSTON, A
    BRITISH MEDICAL JOURNAL, 1969, 4 (5677): : 209 - &
  • [34] Thrombotic microangiopathy associated with monoclonal gammopathy
    Ravindran, Aishwarya
    Go, Ronald S.
    Fervenza, Fernando C.
    Sethi, Sanjeev
    KIDNEY INTERNATIONAL, 2017, 91 (03) : 691 - 698
  • [35] A case of thrombotic microangiopathy associated with polymyositis
    Fukuda, Makoto
    Mizuno, Hiroki
    Hiramatsu, Rikako
    Sekine, Akinari
    Kawada, Masahiro
    Hasegawa, Eiko
    Yamanouchi, Masayuki
    Suwabe, Tatsuya
    Hoshino, Junichi
    Sawa, Naoki
    Takaichi, Kenmei
    Kinowaki, Keiichi
    Ohashi, Kenichi
    Fujii, Takeshi
    Miyazono, Motoaki
    Ubara, Yoshifumi
    CLINICAL NEPHROLOGY, 2021, 95 (06) : 339 - 344
  • [36] Thrombotic microangiopathy associated with the hypereosinophilic syndrome
    Liapis, H
    Ho, AK
    Brown, D
    Mindel, G
    Gleich, G
    KIDNEY INTERNATIONAL, 2005, 67 (05) : 1806 - 1811
  • [37] Gemcitabine-associated thrombotic microangiopathy
    Humphreys, BD
    Sharman, JP
    Henderson, JM
    Clark, JW
    Marks, PW
    Rennke, HG
    Zhu, AX
    Magee, CC
    CANCER, 2004, 100 (12) : 2664 - 2670
  • [38] Thrombotic microangiopathy and associated renal disorders
    Barbour, Thomas
    Johnson, Sally
    Cohney, Solomon
    Hughes, Peter
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (07) : 2673 - 2685
  • [39] Proteasome inhibitor associated thrombotic microangiopathy
    Yui, Jennifer C.
    Van Keer, Jan
    Weiss, Brendan M.
    Waxman, Adam J.
    Palmer, Matthew B.
    D'Agati, Vivette D.
    Kastritis, Efstathios
    Dimopoulos, Meletios A.
    Vij, Ravi
    Bansal, Dhruv
    Dingli, David
    Nasr, Samih H.
    Leung, Nelson
    AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (09) : E348 - E352
  • [40] Chemotherapy-Associated Thrombotic Microangiopathy
    Aklilu, Abinet M. M.
    Shirali, Anushree C. C.
    KIDNEY360, 2023, 4 (03): : 409 - 422
12345